PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK by Lu, Tao et al.
Oncotarget83017www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/             Oncotarget, 2016, Vol. 7, (No. 50), pp: 83017-83030 
PRIMA-1Met suppresses colorectal cancer independent of p53 by 
targeting MEK
Tao Lu2,*, Yanmei Zou1,*, Guogang Xu3, Jane A. Potter4, Garry L. Taylor4, Qiuhong 
Duan2, Qin Yang5, Huihua Xiong1, Hong Qiu1, Dawei Ye1, Peng Zhang1, Shiying Yu1, 
Xianglin Yuan1, Feng Zhu2, Yihua Wang6, Hua Xiong1
1Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, 430030, China
2Department of Biochemistry and molecular biology, School of Basic Medicine, Huazhong University of Science and Technology, 
Wuhan, 430030, China
3Nanlou Respiratory Department, Chinese PLA General Hospital, Beijing, 10083, China
4BioMedical Research Complex, University of St Andrews, St Andrews, KY16 9ST, UK
5Department of Pathology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, 430030, China
6Biological Sciences, Faculty of Natural and Environmental Sciences, University of Southampton, Southampton SO17 1BJ, UK
*These authors have contributed equally to this work
Correspondence to: Hua Xiong, email: cnhxiong@163.com
Keywords: PRIMA-1Met, MEK, p53, colorectal cancer, tumorigenesis
Received: October 17, 2015    Accepted: October 10, 2016    Published: October 27, 2016
ABSTRACT
PRIMA-1Met is the methylated PRIMA-1 (p53 reactivation and induction of massive 
apoptosis) and could restore tumor suppressor function of mutant p53 and induce p53 
dependent apoptosis in cancer cells harboring mutant p53. However, p53 independent 
activity of PRIMA-1Met remains elusive. Here we reported that PRIMA-1Met attenuated 
colorectal cancer cell growth irrespective of p53 status. Kinase profiling revealed 
that mitogen-activated or extracellular signal-related protein kinase (MEK) might 
be a potential target of PRIMA-1Met. Pull-down binding and ATP competitive assay 
showed that PRIMA-1Met directly bound MEK in vitro and in cells. Furthermore, the 
direct binding sites of PRIMA-1Met were explored by using a computational docking 
model. Treatment of colorectal cancer cells with PRIMA-1Met inhibited p53-independent 
phosphorylation of MEK, which in turn impaired anchorage-independent cell growth in 
vitro. Moreover, PRIMA-1Met suppressed colorectal cancer growth in xenograft mouse 
model by inhibiting MEK1 activity.
Taken together, our findings demonstrate a novel p53-independent activity of 
PRIMA-1Met to inhibit MEK and suppress colorectal cancer growth.
INTRODUCTION
Colorectal cancer (CRC) is the third most common 
cancer with nearly 1.4 million new cases in 2012. Based 
on the lesions within colon or rectum, CRC varies in 
terms of biological characteristics and carcinogenic 
mechanisms [1]. Several intracellular signaling pathways 
such as Ras/Raf/MEK/ERK, PI3k/Akt, Wnt/β-catenin and 
p53 are frequently dysregulated in CRC [2–4]. Notably, 
p53 missense or nonsense mutations constantly occur 
in approximately 40-50% of sporadic CRC, causing 
therapeutic resistance and poor prognosis [5].
p53 is a key tumor suppressor regarded as the 
“guardian of the genome”. Once activated in response 
to a variety of stress, p53 elicits potent inhibition of 
tumorigenesis, leading to cell cycle arrest, apoptosis, 
senescence and autophagy [6–8]. However, mutant p53 not 
only abrogates tumor suppressor functions of wild-type 
p53 but also acquires an oncogenic “gain-of-function” 
defined as the ability for malignant proliferation, invasion, 
metastasis and anti-apoptotic effect [9]. Therefore, a 
promising strategy to treat cancer with mutant p53 via 
restoring wild-type p53 function has been pursued. Several 
small molecules such as PRIMA-1, APR-246 (PRIMA-
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1Met), CP-31398, MIRA have been shown to restore wild-
type activity to mutant p53 and induce massive p53-
dependent apoptosis [10–13].
PRIMA-1 is one of chemical compounds originally 
identified by screening a library of low-molecular-
weight compounds [10]. PRIMA-1Met, as methylated 
analog of PRIMA-1, could enhance killing efficacy. 
Biochemical analysis demonstrated that either PRIMA-1 
or its methylated version is converted into active product 
named methylene quinuclidinone (MQ), which in turn 
covalently binds to several cysteine (Cys) residues 
in the DNA-binding domains of p53 and restores 
functional conformation of wild-type p53 [14]. Recent 
reports revealed other targets of PRIMA-1Met such as 
oxidosqualene cyclase and selenoprotein thioredoxin 
reductase 1 (TrxR1) which are sufficient to suppress 
cancer cell growth irrespective of p53 mutation status [15, 
16]. Therefore, identifying potential targets of PRIMA-1Met 
is important to the development of new cancer therapy 
approaches.
The mitogen-activated protein kinase (MAPK) 
pathway Ras/Raf/MEK/ERK is often aberrantly activated 
in CRC and plays a critical role in multiple cellular 
processes including proliferation, transformation, 
apoptosis and senescence [17]. Generally, constitutive 
activation of MAPK cascades is stimulated by mutant 
Ras because activating K-Ras mutations occur in 
approximately 37-45% CRC [18]. So far, no K-Ras mutant 
inhibitors are available for clinical practice [19, 20]. MEK 
is a core downstream effector of Ras/Raf kinases and 
appears as a promising alternative for therapeutic strategy 
targeting Ras-activated MAPK pathway [21].
In the present study, we reported that PRIMA-1Met 
attenuated colorectal cancer cell growth irrespective of 
mutant p53 status. In p53 null or p53 wild-type HCT116 
colorectal cancer cells, we demonstrated that PRIMA-
1Met effectively inhibited cell proliferation and anchorage 
independent growth. Furthermore, we showed that 
PRIMA-1Met directly bound MEK kinase and suppressed 
its activity both in vitro and in cells. Moreover, in vivo 
animal experiments confirmed that PRIMA-1Met inhibited 
MEK activity to suppress the growth of colorectal cancer 
xenografts.
RESULTS
PRIMA-1Met inhibits the proliferation and 
growth of CRC cells independent of p53 status
The chemical structure of PRIMA-1Met was shown 
in Figure 1A. To evaluate p53-independent efficacy 
of PRIMA-1Met, we selected a series of CRC cell lines 
representative of different TP53 heterogeneity, including 
TP53wt (HCT116wt and LOVO), TP53mut (SW480, DLD-
1 and HT29) and TP53neg (HCT116neg). p53 protein 
expression level and genotypes of these cell lines were 
presented (Supplementary Figure S1 and Supplementary 
Table S1). MTS assay showed that the treatment of 
different cells with 25 uM PRIMA-1Met for 12 h or 24 h led 
to similar suppression of cell growth, indicating that CRC 
cells with different TP53 status were generally sensitive 
to PRIMA-1Met (Figure 1B). Meanwhile, we treated the 
cells with different concentrations of PRIMA-1Met for 
24 h. MTS assay showed that PRIMA-1Met reduced the 
viability of all six CRC cell lines in a dose-dependent 
manner (Figure 1C). Notably, the inhibitory effect of 
PRIMA-1Met at concentrations less than 50 umol/L showed 
no significant difference among the cells (Figure 1C). 
However, high dosage of PRIMA-1Met (75 uM) triggered 
apoptosis, especially in cells harboring mutant TP53 
(Supplementary Figure S2A-S2D).
Next we examined the effect of PRIMA-1Met on 
CRC cell growth, and the results showed that PRIMA-1Met 
inhibited the growth of three cell lines: TP53wt HCT116wt, 
TP53mut SW480, and TP53neg HCT116neg (Figure 1D), 
confirming that the inhibitory effect of PRIMA-1Met on 
CRC cell growth is independent of TP53 status.
To further investigate whether the effect of PRIMA-
1Met on cell proliferation is dependent on TP53, we 
compared the effects of PRIMA-1Met in SW480 or DLD-1 
cells transfected with sh-mock or sh-TP53 plasmid (Figure 
1E and Supplementary Figure S3A). The viability of sh-
mock or sh-TP53 cells exhibited no significant difference 
(Figure 1F and Supplementary Figure S3B). Taken 
together, these results suggest that the inhibitory effects 
of PRIMA-1Met on CRC cell proliferation and growth are 
independent of p53 status.
PRIMA-1Met inhibits CRC cell colony formation 
and EGF-induced cell transformation 
independent of p53 status
Next, we determined the effect of PRIMA-1Met on 
anchorage-independent growth of cancer cells. Colony 
formation assay showed that PRIMA-1Met markedly 
inhibited anchorage-independent growth of HCT116wt, 
SW480 and HCT116neg cells in a concentration dependent 
manner (Figure 2A–2C). In particular, PRIMA-1Met at 
50 uM significantly decreased more than 70% of colony 
formation in all 3 cell lines compared to control (P<0.05). 
Even at the lower concentration of 25 uM, PRIMA-1Met 
caused approximate 30% decrease of colony formation in 
soft agar. Our data showed no significant differences in 
dose-dependent inhibition by PRIMA-1Met among TP53wt, 
TP53mut and TP53neg cells.
We further accessed whether PRIMA-1Met could 
inhibit EGF-promoted neoplastic cell transformation in 
immortalized normal cells. We found that PRIMA-1Met 
significantly inhibited EGF induced anchorage-independent 
growth of JB6 P+, an immortalized normal skin cell line 
with impaired p53 function (Figure 2D). These data strongly 
suggest that p53 status is not indispensable for PRIMA-1Met 
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mediated inhibition of anchorage-independent growth and 
EGF-induced cell transformation.
Kinase profiling identifies PRIMA-1Met as a 
potential MEK inhibitor
To understand the mode of action of anti-tumor 
activity of PRIMA-1Met, we performed in vitro kinase 
profiling assay using Millipore’s Kinase Profiler (Table 1). 
The results showed that MEK1 or MEK2 kinase activity 
was significantly suppressed by PRIMA-1Met at the 
concentration of 25 uM. At the same concentration, 
PRIMA-1Met had little effect on EGFR, MAPK1/2 and 
RSK1/2, which were key kinases in Ras/Raf/MEK/ERK 
pathway. These data suggest that MEK is a strong candidate 
target of PRIMA-1Met compared to other screened kinases.
Figure 1: PRIMA-1Met inhibited the proliferation of CRC cells with different p53 status. A. Chemical structure of PRIMA-
1Met. B. CRC cells with different p53 status were treated with 25 uM PRIMA-1Met for 12 or 24 h. The cell viability was measured by MTS 
assay. C. Six colorectal cancer cells were exposed to PRIMA-1Met with various concentrations for 24 h and cell viability was measured by 
MTS assay. D. 1×106 HCT116wt, HCT116neg or SW480 cells were treated with 25 uM PRIMA-1Met or control. Growth curve was measured 
by counting cell number at indicated time point. *P<0.05. PRI: PRIMA-1Met. E. SW480 cells were transiently transfected with sh-TP53 
or sh-mock and p53 expression was analyzed by Western blot analysis. F. SW480 cells transfected with sh-mock or sh-TP53 were treated 
with various concentrations of PRIMA-1Met for 24 h and cell viability was measured by MTS assay. All data were shown as mean ± SEM 
from triplicate experiments.
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Figure 2: PRIMA-1Met inhibited anchorage-independent growth of colorectal cancer cells and EGF-induced neoplastic 
transformation of JB6 P+ cells. A-C., Representative images of colony formation. Cells were seeded in soft agar with the addition of 
different concentration of PRIMA-1Met (0, 12.5, 25, 50 uM) and cultured for 7 days (SW480 and HCT116neg) or 10 days (HCT116wt), then 
colonies were counted. Data were shown as mean ± SEM from triplicate experiments. **P<0.01 vs. vehicle group. PRI: PRIMA-1Met. D. JB6 
P+ cells were cultured with or without EGF (10 ng/ml) and different concentrations of PRIMA-1Met (0, 25, 50 uM) for 7 days, then colonies 
were counted. Data were shown as mean ± SEM from triplicate experiments. * P<0.05; **, P<0.01 vs. EGF single group. PRI: PRIMA-1Met.
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PRIMA-1Met inhibits MEK kinase activity in vitro 
and in cells
To confirm that PRIMA-1Met could inhibit MEK 
activity, we conducted in vitro kinase assay by using 
inactive ERK1 as a substrate of MEK and MEK 
inhibitor AZD6244 as a positive control. We found that 
the phosphorylation of ERK was potently decreased by 
PRIMA-1Met in a dose dependent manner (Figure 3A).
Next, we detected MEK kinase activity in 
colorectal cancer cells and found that its activity was 
significantly elevated in six colorectal cancer cells 
compared with normal colon cells (Figure 3B). When 
colon cancer cell lines HCT116wt and HCT116neg 
were treated with PRIMA-1Met, The phosphorylation 
of downstream molecules of MEK such as ERK1/2 
and RSK2 was dramatically attenuated with PRIMA-
1Met concentration more than 25 uM (Figure 3C, 3D). 
However, there were no significant differences in MEK 
inhibition between HCT116wt and HCT116neg cells, 
indicating that p53 status does not interfere with PRIMA-
1Met induced MEK inactivity.
To further exclude p53-dependent regulatory 
mechanisms, we depleted the expression of mutant p53 in 
SW480 cells by shRNA and found that depletion of p53 
showed minimal effect on the attenuation of MEK activity 
after PRIMA-1Met treatment (Figure 3E). Collectively, 
these data confirm that PRIMA-1Met inhibits MEK activity 
independent of p53 status.
PRIMA-1Met binds MEK directly in vitro and ex 
vivo
To better understand PRIMA-1Met-induced inhibition 
of MEK activity, we wondered whether PRIMA-1Met 
could interact with MEK. We docked PRIMA-1Met to 
MEK monomer using automated docking tool AutoDock 
4 [22]. The results showed that PRIMA-1Met bound to the 
ATP-binding pocket of MEK1 monomer (Figure 4A). The 
oxygen atom of PRIMA-1Met could form hydrogen bond 
Table 1: Kinase profiling results of PRIMA-1Met
Kinase Activity Kinase Activity
ALK 90 JNK3(h) 96
AMPKα1(h) 94 KDR(h) 93
Aurora-A(h) 83 MAPK1(h) 75
Aurora-B(h) 91 MAPK2(h) 80
B-Raf (h) 80 MEK1(h) 35
CDK1/cyclinB(h) 94 MEK2(h) 48
CDK2/cyclinA(h) 102 mTOR(h) 86
CDK3/cyclinE(h) 73 p70S6K(h) 90
C-MET(h) 60 PDK1(h) 76
C-RAF(h) 92 PKBα(h) 110
cSRC(h) 67 PKBβ(h) 100
EGFR(h) 95 PKCα(h) 88
FGFR1(h) 83 PKCδ(h) 92
GSK3α(h) 105 Rsk1(h) 88
GSK3β(h) 110 Rsk2(h) 79
IGF-1R(h) 92 Src(T341M)(h) 110
IKKα(h) 94 TGFBR1 (h) 93
IKKβ(h) 90 PI3K (p110α/p85α) (h) 97
JNK1α1(h) 70 PI3K (p110 β/p85α) (h) 90
JNK2α2(h) 84 PI3K (p110δ/p85α) (h) 94
Kinase screening assay was performed according to Millipore’s Kinase Profiler protocols. Briefly, the reaction concentration 
of PRIMA-1Met was set at 100 µM and the concentration of ATP at 10 µM. Scores for each kinase were represented as the 
percent (%) of kinase activity after PRIMA-1Met treatment.
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with the sulfur group of Cys207 and Met143, and the 
carboxylate group of Asp208 (Figure 4B).
Next we performed ATP competitive binding assay 
by using PRIMA-1Met-conjugated Sepharose 4B beads in 
vitro. Compared with Sepharose 4B beads alone, PRIMA-
1Met-conjugated Sepharose 4B beads could pull-down 
MEK and their affinity was impaired by the presence of 
ATP (Figure 4C). Furthermore, immunoprecipitation assay 
in HCT116neg cells confirmed the binding of PRIMA-1Met 
to endogenous MEK (Figure 4D). Collectively, these data 
provide strong evidence that PRIMA-1Met could directly 
bind MEK in ATP-binding pocket in vitro and in cells.
Figure 3: PRIMA-1Met inhibited kinase activity of MEK in vitro and in cells. A. Representative results of in vitro kinase assay. 
Inactive ERK1 protein was used as a substrate and mixed with active MEK kinase and different doses of PRIMA-1Met. The phosphorylation 
level of ERK1 (Thr202/Tyr204) was detected by Western blot analysis. Total MEK was used as loading control and MEK inhibitor AZD6244 
was used as a positive control. B. Western blot analysis of MEK protein expression level in six colorectal cancer cell lines and normal colon 
epithelial cell line FHC. The activation of MEK signaling was detected in HCT116neg C., HCT116wt D. and SW480 E. cells. After starvation 
in serum-free medium for 24 h, cells were treated with different doses of PRIMA-1Met for 12 h and then treated with 5 ng/ml EGF for 30 
min. AZD6244 was used as a positive control. Data were representative results from three independent experiments.
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MEK is indispensable for the anti-tumor activity 
of PRIMA-1Met in vitro
To confirm that PRIMA-1Met attenuated cancer 
cell proliferation and anchorage-independent growth 
via the inhibition of MEK kinase activity, we used 
shRNA to knockdown MEK1 expression in HCT116neg 
or HCT116wt cells (Figure 5A). The depletion of MEK 
abrogated PRIMA-1Met-induced suppression of anchorage-
independent growth of HCT116neg and HCT116wt cells, and 
the magnitude of growth reduction was correlated with the 
efficiency of MEK1 knockdown (Figure 5B).
PRIMA-1Met could induce reactive oxygen species 
(ROS) to mediate p53-independent cell apoptosis [16]. 
Thus it is possible that PRIMA-1Met inhibits CRC cell 
growth by promoting ROS-induced cell apoptosis. To 
test this possibility, we measured endogenous ROS in 
HCT116neg and HCT116wt cells treated with 25 uM PRIMA-
1Met. PRIMA-1Met induced massive production of ROS and 
this was significantly inhibited by ROS scavenger NAC 
(Figure 5C). However, NAC had little effect on PRIMA-1Met 
induced attenuation of anchorage-independent growth of 
HCT116neg and HCT116wt cells (Figure 5D). These results 
indicate that MEK but not ROS predominantly contributes 
to p53-independent anti-tumor activity of PRIMA-1Met.
PRIMA-1Met suppresses CRC growth in 
xenograft mouse model by inhibiting MEK 
activity
To confirm that the anti-tumor activity of PRIMA-
1Met is mediated by MEK in vivo, we established 
subcutaneous xenograft nude mice model implanted with 
HCT116neg or HCT116wt cells. Once the tumor xenografts 
grew to approximately 50 mm3, the mice were randomly 
assigned to three groups: vehicle (treated with PBS); 
lower dose of PRIMA-1Met (20 mg/kg); and higher dose of 
PRIMA-1Met (100 mg/kg). PRIMA-1Met markedly reduced 
tumor size in both HCT116neg and HCT116wt derived 
xenografts in a dose dependent manner (Figure 6A). 
Compared to vehicle group, PRIMA-1Met (20 mg/kg or 
100 mg/kg) significantly inhibited average tumor volume 
(P < 0.05). In addition, body weight was not significantly 
affected by PRIMA-1Met (Figure 6B), indicating that 
treatment dose of PRIMA-1Met was well tolerated by the 
mice.
Immunohistochemical analysis of tumor samples 
showed that the phosphorylation of ERK1/2 was 
substantially reduced in treatment groups compared 
to vehicle group. Additionally, PRIMA-1Met inhibited 
HCT116neg and HCT116wt cell proliferation because 
Figure 4: PRIMA-1Met specifically binds MEK in vitro and in vivo. A. Computational binding model of PRIMA-1Met in 
proposed ATP-binding pocket of MEK1 monomer. PRIMA-1Met was shown as colored sphere and MEK1 monomer as cartoon. B. The 
proposed binding-position of hydrogen bonds between PRIMA-1Met and MEK1 was indicated. C. Pull-down assay was conducted in vitro 
by incubating 600 ug HCT116neg cell lysates with PRIMA-1Met-Sepharose 4B beads followed by Western blot analysis. D. In vivo ATP 
competitive binding assay was conducted by incubating 300 ng active MEK1 protein with 100 ul PRIMA-1Met-Sepharose 4B beads and 
various concentrations of ATP (0, 10, 100 uM) followed by Western blot analysis. Sepharose 4B only beads were used as negative control. 
Data shown were representative of three independent experiments.
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Figure 5: Knockdown of MEK1 decreases the sensitivity of colorectal cancer cells to PRIMA-1Met. A. HCT116neg or 
HCT116wt cells were transfected with sh-mock or sh-MEK1. Knockdown efficiency was evaluated by Western blot analysis. B. HCT116neg 
or HCT116wt cells transfected with sh-mock or sh-MEK1 were treated with 12.5 and 25 uM PRIMA-1Met for 7 days and colony formation 
in soft agar was assessed. Data were shown as mean ± SEM. AZD6244 was used as a positive control. *P<0.05. C. HCT116neg cells were 
treated with 25 uM PRIMA-1Met in the presence or absence of NAC (5 mM) for 12 or 24 h and stained with 20 uM DCFHDA for 30 min. 
The mean fluorescent intensity was measured by flow cytometer and normalized to vehicle group. Data were shown as mean ± SEM from 
triplicate experiments. **P<0.01 vs. vehicle group. D. Cells were seeded in soft agar with the addition of 25 uM PRIMA-1Met alone or in 
combination of 5mM NAC and cultured for 7 days. Then colony formation was counted. Data represented mean ± SEM. **P<0.01 vs. 
control.
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Figure 6: PRIMA-1Met suppresses tumor growth in vivo by inhibiting MEK activity. A. Mice bearing HCT116neg or HCT116wt 
tumors were treated with PBS, PRIMA-1Met (20 mg/kg or 100 mg/kg). Tumor volume was measured twice a week and data were represented 
as mean ± SEM. *P<0.05; **P<0.01 vs. vehicle group. B. The body weight of mice in each group was measured and recorded once a week. 
Data were shown as mean ± SEM. C. Immunohistochemical staining of Ki-67 and phosphorylated ERK1/2 in paraffin embedded sections 
of tumor xenografts. Scale bar: 50 um. *P<0.05; **P<0.01. D. The levels ofp-ERK1/2, T-ERK1/2 and p-p90RSK in the dissected xenografts 
were determined by Western blot analysis.
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fewer cells were positively stained with proliferation 
marker Ki-67 compared to vehicle group (Figure 6C). 
Western blot analysis of tumor samples showed that the 
phosphorylation of ERK1/2 was substantially suppressed 
in treatment groups compared to vehicle group in a dose 
dependent manner (Figure 6D). Taken together, our data 
indicate that PRIMA-1Met inhibits CRC growth in vivo 
independent of p53 status by suppressing MEK activity.
DISCUSSION
Tumor suppressor p53 is encoded by TP53 gene 
which is frequently mutated in half of all human cancers, 
including breast cancer, multiple myeloma, lung cancer 
and colorectal cancer [23]. The most mutations in TP53 
such as Y220C or R175H are clustered within the DNA-
binding domain and thus impair transcription activity of 
p53, resulting in the inactivation of p53 targets such as 
p21, Bax, PUMA and Noxa [24]. As a consequence, loss 
of p53 tumor suppressor activity prevents cancer cells 
from p53 mediated cell senescence, cell cycle arrest and 
apoptosis. Moreover, mutant p53 acquires gain-of-function 
to promote malignant phenotypes of cancer [25]. Thus it 
is urgent to develop novel anti-cancer strategies targeting 
mutant p53.
PRIMA-1 and its methylated form PRIMA-1Met 
were originally isolated from the low-molecular-weight 
compounds library for the ability to restore sequence-
specific DNA binding and transcription-dependent 
apoptotic function to mutant p53 in vitro and in vivo [10]. 
Although PRIMA-1Met has demonstrated preferential 
inhibitory effect on cancer cells harboring mutant p53, 
recent studies suggest p53-independent activity of 
PRIMA-1Met. Saha et al. found that PRIMA-1Met induced 
apoptosis via p53-independent Noxa induction [26]. 
Grinter et al. found that PRIMA-1Met exerted anti-cancer 
effect by the inhibition of oxidosqualene cyclase (OSC), 
a key enzyme involved in cholesterol synthetic pathway 
[15]. Because p53 family members p63 and p73 have 
similar sequence homology to p53 in DNA binding 
domains, PRIMA-1Met was found to restore mutant p63 
and p73 with apoptotic function irrespective of p53 
status [27]. Meanwhile, PRIMA-1Met could induce ROS 
generation and cause p53-independent massive cell death 
by converting TrxR1 to NADPH oxidase or impairing 
GSH metabolism [16, 28]. These observations prompted 
us to evaluate p53 independent ant-tumor activities of 
PRIMA-1Met.
In the present study, we first used PRIMA-1Met 
to treat six colorectal cancer cell lines with different 
p53 status. We found that PRIMA-1Met inhibited the 
proliferation and growthof all cell lines in a dose and time 
dependent manner, and high dose of PRIMA-1Met triggered 
cell apoptosis regardless of p53 status. In addition, we 
found that treatment with 25 or 50 uM PRIMA-1Met 
caused G2/M arrest in HCT116neg cells (Supplementary 
Figure S4), consistent with previous study [29]. Moreover, 
SW480 and DLD-1 cell lines with depleted mutant p53 
were as sensitive as their parental cells to PRIMA-1Met 
treatment, demonstrating that PRIMA-1Met could suppress 
CRC cell growth in a p53-independent manner.
Kinase signaling pathways, such as Ras/Raf/
MEK and PI3-K/Akt/mTOR cascades, are generally 
hyperactivated and contribute to cancer cell proliferation, 
migration, invasion and chemoresistance [30]. Therefore, 
we performed kinase profiling assay by screening total 40 
kinases and identified MEK kinase as a potential target 
that mediates p53-independent anti-tumor activity of 
PRIMA-1Met. MEK kinase and its downstream effectors 
are consistently activated owing to aberrant mutant 
activation of Ras and B-Raf in colorectal cancer [31]. 
Once activated, MEK1 and MEK2 form heterodimer 
kinase and consecutively mediate downstream ERK1/
ERK2 phosphorylation. Several selective and allosteric 
MEK inhibitors that bind non-ATP competitive site, 
such as Trametinib, Cobimetinib, MEK162, AZD6244 
and PD-0325901, have shown promise in preclinical 
and clinical studies [32–34]. In contrast, we speculated 
that PRIMA-1Met directly binds MEK in the ATP-binding 
pocket based on the results of automated docking 
analysis, pull-down binding and ATP competitive assay. 
Thus the mode of action of PRIMA-1Met in inhibiting 
MEK activity seems to be different from that of MEK 
inhibitors binding non-ATP competitive site. Further 
studies are needed to compare the efficacy of PRIMA-
1Met and other MEK inhibitors.
By detecting the phosphorylation of MEK substrate 
ERK, we showed that PRIMA-1Met potently inhibited 
MEK kinase activity in CRC cells in a dose dependent 
manner. More importantly, knockdown of mutant p53 in 
SW480 did not affect the inhibition of MEK activity by 
PRIMA-1Met, confirming that PRIMA-1Met could inhibit 
MEK kinase activity in cells with different p53 status. 
Moreover, in vivo study showed that PRIMA-1Met inhibited 
MEK activity, leading to significant tumor regression in 
HCT116neg and HCT116wt xenograft model compared with 
vehicle group. These in vitro and in vivo data indicate that 
PRIMA-1Met is a novel MEK1 inhibitor.
In this study we depleted endogenous MEK1 in 
CRC cells to investigate whether MEK1 is indispensable 
for anti-tumor activity of PRIMA-1Met since many small 
molecules that targeting the main target have off targets 
[35, 36]. As expected, the depletion of MEK1 abrogated 
PRIMA-1Met induced suppression of CRC cell growth. To 
avoid the confounding potential of ROS, which could be 
induced by PRIMA-1Met and mediate p53-independent 
cancer cell apoptosis [16], we further assessed ROS 
level and found that ROS production was induced after 
PRIMA-1Met treatment. However, ROS scavenger NAC 
only slightly compensated for PRIMA-1Met induced 
CRC cell growth suppression. Collectively, these results 
demonstrate that direct binding to MEK and inhibiting its 
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activity is the main, if not exclusive, mechanism by which 
PRIMA-1Met suppresses CRC independent of p53 status.
In conclusion, we provide the first lines of 
evidence that PRIMA-1Met inhibits colorectal cancer cell 
proliferation and tumor growth predominately by directly 
targeting MEK in p53 independent manner. Consequently, 
targeting both MEK and mutant p53 by PRIMA-1Met 
may allow us to initiate new strategy for the treatment 
of malignant colorectal cancer that harbors both hyper-
activated Ras/Raf/MEK signaling and p53 mutation.
MATERIALS AND METHODS
Cell culture and transfection
HCT116neg, HCT116wt, LOVO, DLD-1, SW480, 
HT-29 and JB6 P+ mouse skin epidermal cells were 
obtained from American Type Culture Collection 
(ATCC). HCT116neg, HCT116wt and HT-29 cells were 
cultured in McCoy’s 5a and other colorectal cancer 
cells were cultured in RPMI-1640 supplemented with 
10% fetal bovine serum (FBS) and 1% antibiotic. JB6+t 
mouse skin epidermal cells were cultured in Minimum 
Essential Medium (MEM) supplemented with 5% 
FBS and 1% antibiotic. Cells were cultured at 37°C 
in a 5% CO2 incubator. Lentivirus shRNAs pLKO.1-
sh-mock, pLKO.1-sh-p53 (#1:TRCN0000003756, 
#2:TRCN0000003758) and pLKO.1-sh-MEK 
(#1:TRCN0000002314, #2:TRCN0000002315) were 
ordered from Thermo Scientific (Huntsville, AL, USA), 
and co-transfected with packaging vectors (pMD2.0G 
and psPAX from Addgene) into HEK-293T package cells 
by using Lipofectamine 2000 (Thermo Scientific, MA, 
USA). 36 hours after transfection, cell supernatants were 
harvested, filtered and used to infect target cells. 24 hours 
after infection, cells were supplemented with 8 ug/ml 
puromycin to select stable cell lines and RNAi efficiency 
was confirmed by immunoblotting. PRIMA-1Met was 
purchased from Tocris Bioscience (R&D Systems, MN, 
USA). AZD6244 was purchased from Array BioPharma 
(Boulder, CO, USA).
MTS assay
The cells were seeded (1×103/well) in 96-well plates 
and cultured overnight. Cells were treated with different 
concentrations of PRIMA-1Met and cell proliferation 
inhibition was measured by MTS assay (Promega, WI, 
USA) according to the manufacturer’s instructions.
Anchorage-independent cell growth assay
A total of 8,000 cells were suspended in 1 ml 
solidified Basal Medium Eagle containing 10% FBS and 
added to 0.33% top agarose with various concentrations of 
PRIMA-1Met. A base layer of 0.6% agarose was placed at 
the bottom of top agar. Three weeks after seeding, colonies 
were counted in low-power field of light microscope 
using the Image-Pro Plus Software (vs.4) program (Media 
Cybernetics).
Kinase profiling
Kinase profile assay was performed according to 
Millipore’s Kinase Profiler protocols. The concentration 
of PRIMA-1Met and ATP for each kinase analysis was set 
at 100 uM and 10 uM, respectively.
Molecular modeling
Briefly, the PDB files of compound PRIMA-1Met 
was generated from the PRODRG server [37]. The X-ray 
crystallographic structures of MEK-1/2 (PDB code: 
1S9I [38]) were downloaded from Protein Data Bank 
and prepared by using the Protein Preparation Wizard 
in Maestro v9.2. Hydrogen atoms were added to the 
complexes consistently with a pH of 7 and water molecules 
were deleted. Ligand docking the compound to MEK-1/2 
monomer was accomplished using the automated docking 
tool AutoDock 4. Ten independent runs were carried out to 
yield ten AutoDock docking solutions, which were ranked 
by the calculated energy favorable scores. Top hits based 
on hydrogen-bond interactions were considered as top-
ranked conformations of docked complex.
In vitro kinase assay
Active MEK1 (100 ng) and its inactive substrate 
ERK1 (1 ug) were purchased from Millipore (Temecula, 
CA, USA), mixed in the presence of various doses of 
PRIMA-1Met, and incubated in 100 uM ATP and ×1 
kinase buffer (10 mM MgCl2, 1 mM EDTA, 50 mM Tris-
HCl pH 7.5, 0.01% Brij35, 1 mM DTT; Cell Signaling 
Technology) at 30°C for 30 min. Then the samples were 
resolved in ×6 SDS loading buffer. Phosphorylated ERK1 
and total MEK protein level were analyzed by Western 
blot analysis.
In vitro ATP competitive assay and pull-down 
binding assay
PRIMA-1Met-conjugated Sepharose 4B beads 
(GE Healthcare, Pittsburgh, PA, USA) were prepared 
according to the manufacturer’s instruction. The ATP 
competition assay was conducted by incubating 300 ng 
active MEK1 protein with various concentrations of ATP 
(0, 10, 100 uM) at 4°C for 2 h, followed by incubation 
with 100 ul PRIMA-1Met-conjugated Sepharose 4B 
beads or Sepharose 4B beads only for another 2 h in 
×1 reaction buffer (150 mM NaCl, 50 mM Tris-HCl pH 
7.5, 5 mM EDTA, 0.01% NP40, 1 mM DTT, 0.02 mM 
phenylmethysulfonyl fluoride, 2 ug/ml bovine serum 
albumin and ×1 protease inhibitor mixture). For pull-
down binding assay, HCT116neg cell lysates (600 ug) were 
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incubated with 100 ul PRIMA-1Met-conjugated Sepharose 
4B beads or Sepharose 4B beads only overnight at 4°C, 
then the beads were washed with ×1 wash buffer (50 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1 mM DTT, 0.02 mM 
phenylmethylsulfonyl fluoride and 0.01% NP40). The 
proteins that bound to PRIMA-1Met-conjugated Sepharose 
4B beads were resolved by 10% SDS-PAGE and detected 
by Western blot analysis.
Measurement of ROS
HCT116neg and HCT116wt cells were cultured in six-
well plate and grown to subconfluency. Cells were treated 
with PRIMA-1Met in the presence or absence of NAC 
for indicated time. Then cells were stained with 20 uM 
DCFHDA for 30 min and fluorescence was analyzed using 
flow cytometer in the FITC channel. The fluorescence 
intensity of 15,000 cells was measured by WinMDI 2.8 
software and normalized to vehicle group.
Western blot analysis
Cells were lysed with RIPA buffer (150 mM NaCl, 
50 mM Tris-HCl pH 8.0, 0.25% SOD, 0.1% sodium 
dodecyl sulfate, 1 mM EDTA, 1% NP40 and ×1 protease/
phosphatase inhibitor cocktail). Lysates from mouse 
xenograft were prepared by homogenizing tumor mass in 
RIPA buffer. Proteins were separated by SDS-PAGE and 
transferred to PVDF membranes (Amersham Pharmacia 
Biotech). Membranes were blocked with 5% non-fat 
milk and then probed with appropriate primary antibody 
overnight at 4ºC. Then membranes were washed in PBS 
three times and incubated with horseradish peroxidase-
conjugated secondary antibody. Protein bands were 
visualized using an enhanced chemiluminescence reagent 
kit (Amersham). Antibodies against cleaved caspase 3, 
total MEK1/2, phosphorylated MEK1/2 (Ser217/221), 
phosphorylated ERK1/2 (Thr202/Tyr204), phosphorylated 
p90RSK (Thr359/Ser363) and b-actin were purchased 
from Cell Signaling (Beverly, MA, USA). Antibodies 
against total ERK1/2, total MEK1/2, TP53, p21 and Ki-67 
were from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA).
Xenograft mouse model
Athymic nude mice (6-9 weeks old) were provided 
by SLAC Laboratory Animal Co. Ltd. (Shanghai, China). 
Briefly, cells in logarithmic phase were harvested and 
suspended in cold PBS at 5×106/mL. 1×106 cells (in 200 
μl of PBS) were injected subcutaneously into right flank 
of each mouse. Once the tumor volume reached around 
50 mm3, mice were randomly divided into three groups 
(n=5 each): (i) vehicle group; (ii) 20 mg/kg PRIMA-
1Met-treated group; (iii) 100 mg/kg PRIMA-1Met-treated 
group. PRIMA-1Met or vehicle (PBS) was intraperitoneally 
injected daily for 5 days, stopped for 2 days and reinjected 
for additional 5 days. Tumor volume was measured 
twice a week based on the following formula: volume = 
(Length×Width2)/2. Mice body weight was measured and 
recorded once a week. Mice were euthanized on day 28 
and tumor tissues were dissected for further analysis.
Immunohistochemistry analysis
The tumor samples were fixed in 10% neutral 
formalin solution and embedded in paraffin. Then sections 
were cut into fragments of 6 um, deparaffinized and 
hydrated. Tissues on slides were permeabilized by 0.5% 
Triton X-100 and incubated overnight at 4ºC with primary 
antibodies against Ki67 and phosphorylated ERK1/2. The 
slides were washed by PBS for 5 times and incubated 
with 1:200 dilution of secondary biotinylated antibody 
for 2 h at room temperature. All slides were developed 
using horseradish peroxidase-streptavidin (Santa Cruz 
Biotechnology, CA, USA). Images were taken under 
microscope and signal densities were analyzed using the 
Image-Pro Plus Software (Media Cybernetics).
Statistical analysis
All data were presented as mean values ± SD or 
SE as indicated. The Student’s t test (two groups only) 
or a one-way ANOVA (more than two groups) was used 
for the comparison. p < 0.05 was accepted as statistical 
significance.
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